Left Atrial Appendage (LAA) Occluders
This channel includes news and new technology innovations about Left Atrial Appendage (LAA) Occluders. These close off the LAA in patients with atrial fibrillation to prevent the formation of stroke-causing clots in atrial fibrillation (AFib or AF) patients. LAA occlusion is often indicated for patients who do not tolerate anticoagulation therpy or have bleeding risks associated with use of that therapy.
Dr. Dee Dee Wang with part of Henry Ford Hospital's collection of 3-D printed hearts used for education and to preplan structural heart procedures.
Feature | Medical 3-D Printing | March 03, 2017
March 3, 2017 — A Henry Ford Hospital study found a 100 percent success rate in left atrial appendage (LAA) occlusion...
News | Left Atrial Appendage (LAA) Occluders | January 06, 2017
January 6, 2017 — SentreHeart Inc. announced that it has completed the Stage I enrollment milestone in the aMAZE Trial...
Feature | Left Atrial Appendage (LAA) Occluders | November 07, 2016
November 7, 2016 – Results from the U.S. real-world, post-FDA approval experience of the Watchman device found high...
News | Atrial Fibrillation | October 25, 2016
October 25, 2016 — A recent study from University of Alabama at Birmingham (UAB) researchers published in PLOS ONE ...
News | Left Atrial Appendage (LAA) Occluders | October 20, 2016
October 20, 2016 — SentreHeart Inc. announced in late September the closing of a $35 million Series D round of...
News | Left Atrial Appendage (LAA) Occluders | October 13, 2016
October 13, 2016 — SentreHeart Inc. announced this week it has treated the first patients using the Eclipse Surgical...
The CardioKinetix Parachute device implant shown deployed in the left ventricle of a heart failure patient. The device helps remodel the ventricle to improve the heart's ability to pump blood more efficiently.
Feature | Heart Failure | September 29, 2016 | Abha Mishra
New cardiovascular device therapies for atrial fibrillation (AF) and heart failure (HF) are rapidly evolving with the...
News | Left Atrial Appendage (LAA) Occluders | September 02, 2016
September 2, 2016 — St. Jude Medical Inc. announced the start of the St. Jude Medical Amplatzer Amulet IDE trial of the...
The FDA clearance of the first bioresorbable stent, the Abbott Absorb, the first week of July has been the most popular story so far for all of 2016. It is the first fully dissolving stent approved for the U.S. market and many experts say this technology could be a paradigm shift in coronary and peripheral therapies in the coming years as the technology improves.
Feature | August 05, 2016 | Dave Fornell
August 5, 2016 — Here are the top 20 most popular current content on the Diagnostic and Interventional Cardiology (...
An illustration of a Watchman transcatheter LAA occluder being implanted.
Feature | Left Atrial Appendage (LAA) Occluders | August 01, 2016 | Dave Fornell
Patients with atrial fibrillation (AF or Afib) are high risk for stroke due to the formation of thrombus emboli in the ...
News | Left Atrial Appendage (LAA) Occluders | July 07, 2016
July 7, 2016 — AtriCure Inc. announced the first patient has been enrolled in the FROST study at William Beaumont...
News | Left Atrial Appendage (LAA) Occluders | July 05, 2016
July 5, 2016 — AtriCure Inc. announced that it has received CE Mark for the AtriClip PRO2 Left Atrial Appendage (LAA)...
The Boston Scientific Watchman device is currently the only transcatheter LAA occluder cleared for use in the United States.
Feature | Left Atrial Appendage (LAA) Occluders | May 20, 2016 | Dave Fornell
Atrial fibrillation (AF) affects nearly 6 million Americans and the condition puts them at significantly greater risk...
News | Cath Lab | May 19, 2016
May 19, 2016 — St. Jude Medical Inc. announced results from two cardiovascular clinical trials presented at EuroPCR...
Technology | Left Atrial Appendage (LAA) Occluders | April 29, 2016
April 29, 2016 — AtriCure Inc. announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the AtriClip PRO2...
